Allogene Therapeutics, Inc., a biotechnology company operating within the health care sector, has been making strides in the development of innovative treatments for blood cancers and solid tumors. Specializing in allogeneic chimeric antigen receptor T-cell therapy, the company is dedicated to advancing therapeutic options for patients, particularly those residing in California. Based in South San Francisco, Allogene Therapeutics is listed on the Nasdaq stock exchange, where its shares are traded in USD.
As of December 4, 2025, the company’s stock closed at $1.43. Over the past year, the stock has experienced significant volatility, reaching a 52-week high of $3.78 on February 18, 2025, and a 52-week low of $0.86 on May 13, 2025. This fluctuation reflects the dynamic nature of the biotechnology sector and the challenges inherent in developing cutting-edge therapies.
Allogene Therapeutics has a market capitalization of approximately $323.61 million, indicating its valuation within the industry. The company’s price-to-earnings (P/E) ratio stands at -1.46, which is not uncommon for biotech firms that may not yet be profitable but are focused on research and development.
The company’s mission is centered around the development of allogeneic CAR-T cell therapies, a promising area in cancer treatment. These therapies involve modifying a patient’s T-cells to better recognize and attack cancer cells, offering a potential alternative to traditional treatments. Allogene Therapeutics’ focus on allogeneic approaches, which use donor cells rather than the patient’s own cells, aims to streamline the treatment process and make it more accessible.
For those interested in learning more about Allogene Therapeutics’ mission, offerings, and ongoing research, additional information is available on their website at www.allogene.com . The company continues to engage with the scientific community and investors to further its goals in transforming cancer treatment through innovative biotechnology solutions.
